Search

Displaying results 6241 - 6250 of 10000 in total
  1. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853]. … The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853].

  2. Drug

    Marbofloxacin

    go.drugbank.com/drugs/DB11426
    ExperimentalVet approved

    Marbofloxacin is a carboxylic acid, part of the third generation of antibiotic fluoroquinolones. It is used in veterinary medicine. … A formulation of marbofloxacin combined with clotrimazole and dexamethasone is available under the name Aurizon.

  3. Drug

    Menaquinone 6

    go.drugbank.com/drugs/DB14936
    Investigational

    Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).

  4. Drug

    Bakuchiol

    go.drugbank.com/drugs/DB16102
    Investigational

    Bakuchiol is under investigation in clinical trial NCT03112863 (Comparison of the Cosmetic Effects of Bakuchiol and Retinol).

  5. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

  6. Drug

    BL-1020

    go.drugbank.com/drugs/DB05687
    Investigational

    BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).

  7. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591] … AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.

  8. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (

  9. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  10. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells.